NASDAQ · VOR

Vor Biopharma Inc.

$19.26 +$0.28 (+1.48%) 1D After hours

Key Metrics

$1.03B
Market cap
P/E · TTM
Revenue · TTM
−$883.08M
Net income
EPS · TTM $-141.49
Dividend yield
Free cash flow −$150.65M
Beta · 1Y 1.34
EBITDA · TTM −$371.42M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 29
    The stock moved +15.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 29
  • Jun 10
    From its Apr 2 high, the share price fell 28%.

    Peak close $18.05 on Apr 2; trough close $13.00 on Jun 10. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -28%
  • Mar 31
    The stock moved +21.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 31

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.03B
Enterprise value
Shares outstanding54.2M
52-wk range$6.50 – $53.00
Avg volume · 20D247.5K
Net cash
Book value / share$-24.10
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Vor Biopharma Inc.
IPO dateFeb 5, 2021
Employees76

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC 3,285.3% · —

Financial Health

Current ratio31.15
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$484.70M

Cash Flow · TTM

Operating CF −$149.89M
Capex −$758.00K
Free cash flow −$150.65M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings